跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,224 条关于
“SK Biopharm”
全部
1,224
临床试验
54
药物
461
机构
200
资讯
509
上个月
SK Biopharm Settles US Patent Suit Over Xcopri, Reinforcing Long-Term Market Exclusivity
去年
SK Biopharm and Eurofarma Seek Approval for Cenobamate in Brazil for Epilepsy Treatment
23天前
SK Biopharm licenses Biohaven's Kv7 activator Opakalim in $795M deal, targeting 2029 US launch
9个月前
SK Biopharmaceuticals' Cenobamate and Solriamfetol Receive NMPA Approval for China Market
前天
Japan Approves Ono's XCOPRI (Cenobamate) for Partial-Onset Seizures After Phase 3 Win
6个月前
SK Biopharmaceuticals Acquires Full Control of U.S. R&D Unit with $36 Million Investment to Advance Cancer Pipeline
10个月前
SK Biopharmaceuticals Partners with Interon to Develop First-in-Class Autism Treatment Using Neuroimmune Approach
9个月前
SK Biopharmaceuticals Licenses WT-7695 Radiopharmaceutical Targeting CA9 for Solid Tumors
5个月前
SK Biopharmaceuticals Launches Cenobamate in China, Marking Major Milestone for Epilepsy Treatment
昨天
SK Biopharmaceuticals Licenses Preclinical LRRK2/c-Abl Dual Inhibitor 1ST-104 for Parkinson's in Deal Worth Up to $314.8M
第 1 页,共 51 页
上一页
下一页